CORT Stock Surges 31% With A 5-day Winning Spree On Positive Cancer Trial
Corcept Therapeutics (CORT) – a pharmaceutical company developing drugs for severe metabolic disorders – hit 5-day winning streak, with cumulative gains over this period amounting to a 31%. The company market cap has surged by about $1.1 Bil over the last 5 days, and currently stands at $4.7 Bil.
The stock has YTD (year-to-date) return of 31.1% compared to 1.5% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity, or a trap.
What Triggered The Rally?
[1] Positive Phase 3 Ovarian Cancer Trial Results
- Should You Buy CrowdStrike Stock After Its Recent Pullback?
- BMNR Stock At $23: Buy Ethereum At A Discount?
- Earn 9.4% Today or Buy CROX 40% Cheaper – It’s a Win-Win
- Triggers That Could Ignite the Next Rally In Applied Materials Stock
- Palantir Technologies Stock Can Sink, Here Is How
- Cash Machine Trading Cheap – Webull Stock Set to Run?
- Relacorilant reduced the risk of death by 35% in the ROSELLA trial
- Multiple analyst price target and EPS estimate upgrades followed the announcement
- Impact: Stock jumped ~25% in pre-market trading on the news, Significant increase in trading volume
[2] Analyst Price Target and EPS Upgrades
- Canaccord Genuity raised its price target to $100.00
- HC Wainwright increased Q4 2026 EPS estimates and maintained a $105 price target
- Impact: Reinforced positive investor sentiment, Contributed to sustained upward price movement
Opportunity or Trap?
Below is our take on valuation.
There is not much to fear in CORT stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (For details, see Buy or Sell CORT).
But here is the real interesting point.
You are reading about this 31% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that haven not surged yet.
Returns vs S&P 500
The following table summarizes the return for CORT stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CORT | S&P 500 |
|---|---|---|
| 1D | 3.8% | 0.5% |
| 5D (Current Streak) | 31.4% | 0.1% |
| 1M (21D) | -44.3% | 0.6% |
| 3M (63D) | -37.5% | 3.1% |
| YTD 2026 | 31.1% | 1.5% |
| 2025 | -30.9% | 16.4% |
| 2024 | 55.1% | 23.3% |
| 2023 | 59.9% | 24.2% |
However, big gains can follow sharp reversals – but how has CORT behaved after prior drops? See CORT Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 65 S&P constituents with 3 days or more of consecutive gains and 42 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 17 | 37 |
| 4D | 35 | 0 |
| 5D | 9 | 4 |
| 6D | 3 | 0 |
| 7D or more | 1 | 1 |
| Total >=3 D | 65 | 42 |
Key Financials for Corcept Therapeutics (CORT)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $482.4 Mil | $675.0 Mil |
| Operating Income | $107.3 Mil | $137.0 Mil |
| Net Income | $106.1 Mil | $141.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $194.4 Mil | $207.6 Mil |
| Operating Income | $26.7 Mil | $10.2 Mil |
| Net Income | $35.1 Mil | $19.7 Mil |
While CORT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.